文献速递造血干细胞移植与细胞治疗血栓与止血淋巴瘤

CAR-T细胞治疗后出血与血栓事件的发生率及危险因素

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
PubMed 文献 · Blood Adv · 2021-01-01

该回顾性研究分析了127例接受axi-cel或CD19/CD22双特异性CAR治疗的LBCL或B-ALL成人患者,发现3个月内出血和血栓发生率分别为9.4%和6.3%。出血多与消耗性凝血病特征相关,低基线血小板和≥3级ICANS与出血风险增加相关,严重ICANS亦与血栓风险增加相关。

要点

  • CAR-T治疗后3个月内出血和血栓发生率分别为9.4%和6.3%。
  • 低基线血小板和≥3级ICANS与出血风险增加相关。
  • 严重ICANS患者应密切监测出血和血栓事件,尤其治疗后第一个月内。

核心结论

  • CAR-T治疗后出血和血栓事件发生率分别为9.4%和6.3%,低基线血小板和严重ICANS与出血风险增加相关。

研究设计与样本

  • 回顾性分析2017年至2020年连续接受axi-cel(n=89)或CD19/CD22双特异性CAR(n=38)治疗的LBCL或B-ALL成人患者共127例。

主要发现

  • 12例(9.4%)发生出血,8例(6.3%)发生血栓,axi-cel亚组分别为11.2%和6.7%。
  • 出血发生于第8至30天(中位17.5天),血栓发生于第2至91天(中位29天)。
  • 出血部位包括泌尿生殖道、软组织、颅内、胃肠道和肺部,并与消耗性凝血病特征相关。
  • 单因素分析显示出血患者年龄更大、基线血小板更低(86×10^3/μL vs 178×10^3/μL;P<.01),血小板和纤维蛋白原最低值更低,乳酸脱氢酶升高。
  • ≥3级ICANS与出血增加(50% vs 15%;P=.01)、血栓增加(50% vs 16%;P=.04)及凝血酶原时间延长、低纤维蛋白原血症和D-二聚体升高相关。

关键数值与推荐

  • 多因素logistic回归模型显示低治疗前血小板计数与出血相关。

临床怎么用

  • 血小板减少或严重ICANS患者出血和血栓风险增加,应密切监测,尤其在CAR-T治疗后第一个月内。

局限性

  • 未来需在更大队列中评估CAR-T治疗中系统性凝血病的危险因素及其与神经毒性的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bleeding and thrombotic events are an emerging toxicity associated with chimeric antigen receptor (CAR) therapies. To determine their incidence, we retrospectively analyzed consecutive adult patients (N = 127) with large B-cell lymphoma (LBCL) or B-cell acute lymphoblastic leukemia (B-ALL) treated from 2017 through 2020 with axicabtagene ciloleucel (axi-cel; n = 89) or a bispecific CD19/CD22 CAR (n = 38). Twelve (9.4%) and 8 (6.3%) patients developed bleeding and thrombosis within the first 3 months, respectively. In the axi-cel subgroup, these occurred in 11.2% and 6.7%, respectively. Bleeding occurred between days 8 and 30 (median, 17.5) and thrombosis between days 2 and 91 (median, 29). Bleeding sites included genitourinary, soft tissue, intracranial, gastrointestinal, and pulmonary and were associated with features of consumptive coagulopathy. On univariate analysis, patients with bleeding were older, had lower baseline platelets (86 × 103/μL vs 178 × 103/μL; P < .01), lower platelet and fibrinogen nadirs , and elevated lactate dehydrogenase. Immune effector cell (IEC)-associated neurotoxicity syndrome (ICANS) grade ≥3 was associated with increased bleeding (50% vs 15%; P = .01), thrombosis (50% vs 16%; P = .04), prothrombin time prolongation, hypofibrinogenemia, and elevated D-dimer. Low pretreatment platelet counts were associated with bleeding in a multivariate logistic regression model. Patients with thrombocytopenia or severe ICANS are at increased risk of bleeding and should be closely monitored, particularly within the first month after CAR therapy. Future studies in larger cohorts should assess risk factors for systemic coagulopathies in CAR T therapy, including their association with neurotoxicity.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Johnsrud A, Craig J, Baird J, et al. Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Adv. 2021. PMID: 34521106. doi:10.1182/bloodadvances.2021004716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。